Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice
Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani, Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani
Abstract
Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of β-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a β-catenin-driven transcription program that leads to endothelial-to-mesenchymal transition. TGF-β/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate β-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas.
Keywords: cerebral cavernous malformation; endothelial cells; sulindac metabolites; vascular pathology; β-catenin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Source: PubMed
Tulevat kliiniset tutkimukset
-
Shirley Ryan AbilityLabKiwanis Neurological Research FoundationRekrytointiTBI:n traumaattinen aivovaurioYhdysvallat
-
University of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)Ei vielä rekrytointiaLaskimotromboembolia | Lantion kirurgia | VatsasyöpäkirurgiaYhdysvallat
-
Fundacion para la Investigacion Biomedica del Hospital...Hospital Universitario La FeRekrytointi
-
Lumetry Diagnostics GmbHKarl Landsteiner Institute for Lung Research and Pneumological Oncology; Klinik FloridsdorfEi vielä rekrytointiaKeuhkosairaus, krooninen obstruktiivinen | HyperkapniaItävalta
-
Beijing Suncadia Pharmaceuticals Co., LtdRekrytointi
-
IpsenEi vielä rekrytointia
-
Xiangya Hospital of Central South UniversityEi vielä rekrytointiaPlakkipsoriaasi | DyslipidemiaKiina
-
Halic UniversityEi vielä rekrytointiaUnen laatu | Ruokavalion interventio | Koettu stressi | AivosumuTurkki (Türkiye)
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityEi vielä rekrytointiaMetastaattinen rintasyöpä | Hormonireseptoripositiivinen rintasyöpä | HER2-matala rintasyöpäKiina
-
The 108 Military Central HospitalVietnam Military Medical University; Thanh Phuong Co., LtdEi vielä rekrytointiaSeptinen shokki | Akuutti munuaisvaurioVietnam
-
University Hospital, MontpellierEi vielä rekrytointiaHemipareesi | Spastisuus | Yläraajojen spastisuusRanska
-
Kasr El Aini HospitalRekrytointiIdiopaattinen granulomatoottinen utaretulehdusEgypti